Featured Video

European Academy of Neurology (EAN) and Peripheral Nerve Society (PNS) Guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second Revision

  • CIDP

Watch Dr. Peter Van den Bergh, lead author, take you through the highlights of the guideline.

Videos about CIDP

The GRIPPER study: Quantifying IVIG Treatment-Related Fluctuations in CIDP Using Daily Grip Strength Measurements
Jeffrey A. Allen, MD
University of Minnesota
12:15 MIN
  • CIDP
Learn more about grip strength as an outcome measure in CIDP and how it is utilized in the Gripper Study as a daily measure of treatment-related fluctuations in IVIg-treated patients.
DOWNLOAD PDF
IgG Levels and Wear Off Reflect Administration and Outcome
Carol L. Koski, MD
GBS/CIDP Foundation International
5:51 MIN
  • CIDP
  • GBS
Learn more about how IgG levels and their wear off reflect treatment administration and outcomes in individual IVIG- or SCIG-treated patients with immunodeficiency and peripheral inflammatory neuropathy disorders.
DOWNLOAD PDF
Improving CIDP Diagnosis: The Challenges of Under and Over Diagnosis
Jeffrey A. Allen, MD
University of Minnesota
12:30 MIN
  • CIDP
Understand the challenges associated with accurately diagnosing CIDP
DOWNLOAD PDF
Incidence of GBS and CIDP Following Influenza Vaccination
Peter Donofrio, MD
Vanderbilt University Medical Center, Nashville, TN, USA
25:18 MIN
  • CIDP
  • GBS

Gain an understanding of the existing surveillance data, studies and facts associated with the influenza vaccine as it relates to GBS and CIDP.

DOWNLOAD PDF
NOW PLAYING
12:15
The GRIPPER study: Quantifying IVIG Treatment-Related Fluctuations in CIDP Using Daily Grip Strength...
Learn more about grip strength as an outcome measure in CIDP and how it is utilized in the Gripper Study as a daily measure of treatment-related fluctuations in IVIg-treated patients.
NOW PLAYING
5:51
IgG Levels and Wear Off Reflect Administration and Outcome
Learn more about how IgG levels and their wear off reflect treatment administration and outcomes in individual IVIG- or SCIG-treated patients with immunodeficiency and peripheral inflammatory neuropathy disorders.
NOW PLAYING
12:30
Improving CIDP Diagnosis: The Challenges of Under and Over Diagnosis
Understand the challenges associated with accurately diagnosing CIDP
NOW PLAYING
25:18
Incidence of GBS and CIDP Following Influenza Vaccination

Gain an understanding of the existing surveillance data, studies and facts associated with the influenza vaccine as it relates to GBS and CIDP.

Our Experts on CIDP

Jeffrey A. Allen, MD
University of Minnesota
Jeffrey A. Allen, MD
University of Minnesota
  • CIDP
  • MMN
Dr. Jeffrey Allen is a neuromuscular specialist and clinical investigator at the University of Minnesota in Minneapolis.
Mel Berger, MD, PhD
Medical Research Strategy, CSL Behring
Mel Berger, MD, PhD
Mel Berger, MD, PhD
Medical Research Strategy, CSL Behring
  • CIDP
Mel Berger is a Senior Director, Medical Research Strategy at CSL and Adjunct Professor of Pediatrics and Pathology, Case Western Reserve University. He earned his undergraduate, medical and PhD (in Biochemistry) degrees at Case Western Reserve University in Cleveland.
Michael Lunn, PhD

National Hospital for Neurology and Neurosurgery, Queen Square, London

Michael Lunn, PhD
Michael Lunn, PhD

National Hospital for Neurology and Neurosurgery, Queen Square, London

  • CIDP

Dr Michael Lunn is a Consultant Neurologist, Clinical Lead in Neuroimmunology and Honorary Senior Lecturer at the National Hospital for Neurology and Neurosurgery.

Karissa Gable, MD
Duke University Medical Center in Durham, North Carolina
Karissa Gable, MD
Karissa Gable, MD
Duke University Medical Center in Durham, North Carolina
  • CIDP
Dr. Karissa Gable is a Neuromuscular specialist at Duke University Medical Center in Durham, North Carolina.
What is Chronic Inflammatory
Demyelinating Polyneuropathy (CIDP)?
READ MORE
What are the symptoms of CIDP?
READ MORE
How is CIDP treated?
READ MORE

Slides & Posters about CIDP

IgG Levels and Wear Off Reflect Administration and Outcome
PDF | 1.5 MB
20% Subcutaneous Immunoglobulin for Maintenance Treatment in Chronic Inflammatory Demyelinating Polyneuropathy (PATH): a Randomized, Double-...
PDF | 3.8 MB
Restabilization of chronic inflammatory demyelinating polyneuropathy patients with IVIG: restabilization phase of the PATH study
PDF | 0.98 MB
Clinical Studies for the Treatment of CIDP with Immunoglobulin
PDF | 421 KB
Back to Top